parkinson, Parkinson's research notebook

Six readers

reader	found	score
genetics Open Targets	no genetic evidence; overall 0.01 from other evidence	0.00
cell type Human Protein Atlas	cell type enhanced, including oligodendrocyte progenitor cells; strongest in fibroblasts	0.75
chemistry Open Targets	reachable by antibody	0.45
trials ClinicalTrials.gov	12 Parkinson's trials, 4 stopped	0.73
literature PubMed	2 Parkinson's papers of 1,264	0.85
pathways Reactome	1 pathway; mostly energy	0.60

No case: the score is under the bar. Receipt 10033

receipt 10041: HAS2 in dopamine neurons, braak

power: full sample -0.14 (p 0.573, n 18), 95% CI -0.57 to +0.35. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: -0.14 (p 0.573, n 18). does not hold up.
composition: dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.18 (p 0.465, n 18). could be the mix.
skeptic: leave-one-out range -0.31 to -0.05, sign flips 0; without severely affected donors -0.14 (p 0.573, n 18). fragile.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for HAS2 in dopamine neurons.

case closed: nothing better to follow up.

receipt 10040: HAS2 in oligodendrocytes, braak

power: full sample +0.08 (p 0.767, n 18), 95% CI -0.41 to +0.52. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: +0.12 (p 0.640, n 18). does not hold up.
composition: oligodendrocytes share of nuclei vs axis +0.03 (p 0.915); controlling for it: -0.03 (p 0.922, n 18). could be the mix.
skeptic: leave-one-out range -0.02 to +0.21, sign flips 3; without severely affected donors +0.08 (p 0.767, n 18). fragile.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for HAS2 in oligodendrocytes.

case closed: nothing better to follow up.

loading the receipts